Prior Authorization Criteria

eteplirsen (Exondys 51™) CRITERIA*

☐ Diagnosis of Duchenne Muscular Dystrophy (DMD) with mutation amenable to exon 51 skipping; ICD-10 code: ______________________________

For both the initial and the reauthorization requests, providers must submit documentation of a recent clinical progress note including patient’s current age and weight with the date the weight was obtained; the weight must be dated no more than 30 days before the request date, a copy of the prescription, and the eteplirsen (Exondys 51™) prior authorization form.

INITIAL AUTHORIZATION requests shall also include documentation of:
- the genetic laboratory test result with specific mutation and
- physical function with age appropriate testing tools used to measure physical function.

REAUTHORIZATION requests shall also include documentation of either:
- an increase in the physical function from baseline or
- that baseline physical function has been maintained.

Providers should use the same testing instrument as used in the baseline evaluation for physical function. If re-use of the initial testing instrument is not appropriate, for example, due to change in client status or restricted age range of the testing tool, the provider must explain the reason for the change.

Prior authorization requests for eteplirsen (Exondys 51™) may be approved if the following criteria are met: (Yes should be checked for each statement):

INITIAL AUTHORIZATION: (prior authorization will be issued for, no more than, a six-month duration):

☐ Yes  ☐ No  Males age ≥ 3 years,

☐ Yes  ☐ No  Patient has a diagnosis of Duchenne muscular dystrophy (DMD) with mutation amenable to exon 51 skipping confirmed by genetic testing (attach results of genetic testing),

☐ Yes  ☐ No  eteplirsen (Exondys 51™) is prescribed by or in consultation with a neurologist or a physician who specializes in treatment of DMD; (i.e. pediatric neurologist, cardiologist or pulmonary specialist),

☐ Yes  ☐ No  Patient is on a stable dose of a corticosteroid or has documented reason not to be on this medication,

☐ Yes  ☐ No  Patient is not ventilator dependent,

☐ Yes  ☐ No  Patient is not in medically intractable congestive heart failure,
□ Yes  □ No  Comprehensive progress notes submitted document age appropriate and functional level determination of baseline assessment. Testing tools that can be used to demonstrate physical function include, but are not limited to:

- Baseline 6-Minute Walk Test (6MWT)),
  - OR
- Brooke Upper Extremity Scale (some useful hand function present for use of adaptive technology),
  - OR
- Forced Vital Capacity assessment,

□ Yes  □ No  Request is for FDA approved dosing,

□ Yes  □ No  Copy of prescription is provided,

□ Yes  □ No  Patient’s weight in kilograms and the date weight recorded.

Dates of Weight/Visit: _____________________________________ Weight (in kg) _____

REAUTHORIZATION: (prior authorization will be issued for, no more than, a six-month duration):
□ Yes  □ No  Patient initial authorization criteria for initial treatment are still met,

□ Yes  □ No  Patient has not had significant decline in neuromotor function or forced vital capacity while on eteplirsen (Exondys 51™),

□ Yes  □ No  Statement from prescribing physician that the patient has been compliant with treatment,

□ Yes  □ No  Copy of prescription is provided,

□ Yes  □ No  Patient’s weight in kilograms and the date weight recorded.

Dates of Weight/Visit: _____________________________________ Weight (in kg) _____

Each prescription may be written for 6 months; however the prescription must specify that medication is to be dispensed at no more than four (4) weeks supply at a time. Mississippi Division of Medicaid will only allow a 28 day supply to be dispensed at a time to ensure that the patient tolerates the medication prior to subsequent medication doses being dispensed to the physician clinic/hospital for administration.

*NOTE: Mississippi Division of Medicaid’s coverage of eteplirsen (Exondys 51™) is contingent upon continued FDA approval.

Effective: 4/1/2019
Updated: 2/3/2020 V3